Want to see AU:ALC full AI Analyst Report?
ALC Stock Chart & Stats
AU$0.10
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.10
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.15
Previous CloseN/A
Volume609.88K
Average Volume (3M)796.98K
Market Cap
AU$131.67M
Enterprise ValueAU$127.81
Total Cash (Recent Filing)AU$14.20M
Total Debt (Recent Filing)AU$1.32M
Price to Earnings (P/E)33.8
Beta0.87
Next Earnings
Sep 02, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding1,343,558,700
10 Day Avg. Volume536,053
30 Day Avg. Volume796,979
Financial Highlights & Ratios
PEG Ratio-0.70
Price to Book (P/B)1.57
Price to Sales (P/S)3.38
P/FCF Ratio24.47
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.15Price Target Upside45.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)<0.01
Revenue Forecast (FY)AU$50.15M
Bulls Say, Bears Say
Bulls Say
Recurring Revenue ModelAlcidion’s core business is subscription and support-led software sales to hospitals, producing recurring revenue and multi-year contracts. That model creates predictable cash flows, supports high retention and cross-sell potential across sites, and underpins long-term revenue visibility.
High Gross MarginsAn 88% gross margin is characteristic of software-centric healthcare offerings, indicating scalable unit economics. High gross margins provide room for sustained R&D, sales investment and margin expansion, helping the company leverage revenue growth into improved operating leverage over time.
Material Free Cash Flow ImprovementA dramatic jump in free cash flow and near parity with net income show much stronger cash conversion. Durable cash generation reduces dependence on external financing, funds implementation and product development, and strengthens the balance sheet for multi-year contract delivery.
Bears Say
Negative Operating ProfitabilityDespite strong top-line growth and high gross margins, negative EBIT indicates operating costs (sales, implementation, overhead) are still outpacing core profits. This constrains sustainable earnings, requires continued operating leverage to reach durable profitability, and could pressure margins if growth slows.
Low Return On EquityA ROE below 2% signals limited effectiveness in converting equity into shareholder returns. Over the medium term this suggests capital is not yet earning strong returns, implying either reinvestment that has yet to pay off or structural limits on profitability relative to shareholder capital.
Contract-dependent, Lumpy RevenueRevenue is materially tied to winning and expanding multi-year hospital contracts, which are typically lumpy with long sales and implementation cycles. That structural dependency can produce uneven revenue recognition, require heavy professional services investment, and slow predictable scaling.
Alcidion Group Limited News
ALC FAQ
What was Alcidion Group Limited’s price range in the past 12 months?
Alcidion Group Limited lowest share price was AU$0.08 and its highest was AU$0.14 in the past 12 months.
What is Alcidion Group Limited’s market cap?
Alcidion Group Limited’s market cap is AU$131.67M.
When is Alcidion Group Limited’s upcoming earnings report date?
Alcidion Group Limited’s upcoming earnings report date is Sep 02, 2026 which is in 43 days.
How were Alcidion Group Limited’s earnings last quarter?
Alcidion Group Limited released its earnings results on Feb 25, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of AU$0 by AU$0.001.
Is Alcidion Group Limited overvalued?
According to Wall Street analysts Alcidion Group Limited’s price is currently Undervalued.
Does Alcidion Group Limited pay dividends?
Alcidion Group Limited does not currently pay dividends.
What is Alcidion Group Limited’s EPS estimate?
Alcidion Group Limited’s EPS estimate is 0.
How many shares outstanding does Alcidion Group Limited have?
Alcidion Group Limited has 1,343,558,700 shares outstanding.
What happened to Alcidion Group Limited’s price movement after its last earnings report?
Alcidion Group Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of AU$0. Following the earnings report the stock price went down -4.545%.
Which hedge fund is a major shareholder of Alcidion Group Limited?
Currently, no hedge funds are holding shares in AU:ALC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alcidion Group Limited Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
AU$0.15 (45.00% Upside)
AU$0.15 (45.00% Upside)
Blogger Sentiment
Bullish
AU:ALC Sentiment 100%
Sector Average 66%
Sector Average 66%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
66.66%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.82%
Trailing 12-Months
Company Description
Alcidion Group Limited
Alcidion Group Limited operates as a healthcare technology firm, specializing in the creation and licensing of software products across Australia, New Zealand, and the United Kingdom. Its flagship product, Miya Precision, is a consolidated platform built on the Fast Healthcare Interoperability Resources (FHIR) standard, aimed at enabling intelligent healthcare delivery. The company also supplies Smartpage, a mobile and web-based system designed to streamline hospital communications and task management for clinical and administrative personnel. Additional solutions include Patientrack, a tool for real-time patient monitoring and risk screening; Silverlink, which handles patient administration; and ExtraMed, software dedicated to optimizing clinical and patient flow. Furthermore, Alcidion provides a range of services encompassing product deployment, support and maintenance, systems integration, and data analysis. Founded in 2000 and headquartered in South Yarra, Australia, the company was formerly known as Alcidion Corporation Pty Ltd until its rebranding as Alcidion Group Limited in December 2015.
ALC Stock 12 Month Forecast
Average Price Target
AU$0.15
▲(45.00% Upside)
Technical Analysis
Oneview Healthcare Chess Depository Interests repr 1
―
Pro Medicus Limited
―
Mach7 Technologies
―
Beamtree Holdings Ltd
―
Artrya Limited
―








